| TUPEB02 | Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing: week 24 results of the randomized D2ARLING study | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB03 | Efficacy and safety of switching older adults (≥60 years) from first-line art to B/F/TAF in Kenya - a randomized clinical trial (the B/F/TAF elderly study) | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB04 | Similar inflammatory markers after switching to cabotegravir + rilpivirine long-acting vs. continuing bictegravir/emtricitabine/tenofovir alafenamide: data from the Phase 3b SOLAR study | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB05 | Evaluation of therapeutic concentrations of anti-HIV antibodies 3BNC117/teropavimab and 10-1074/zinlirvirmab through PK-PD modeling and prediction of the washout duration in HIV cure studies | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB06 | Patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b SOLAR study | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB07 | Pharmacokinetic bridging with oral Lenacapavir for missed subcutaneous Q6M dosing | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB14 | Recommendations for missed oral lenacapavir loading doses using population-pharmacokinetics-based simulations | Poster exhibition | Antiretroviral therapies and clinical issues in adults |